GlassScriptPhysician profile
Apurva M Patel
NPI 1902856230
$2,369.25
in general payments reported to CMS, 2019-2025
21 companies · $23.82 in 2025
The $23.82 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $177 · 2021: $381 · 2022: $486 · 2023: $224 · 2024: $219 · 2025: $23.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.08 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $258.25 | 2020-2023 | Opsumit, Uptravi |
| Medtronic, INC. | $230.39 | 2021-2024 | Symplicity G3, Corevalve Evolut R |
| Abbott Laboratories | $216.50 | 2022-2025 | Coroflow, Dragonfly Opstar, Omnilink Elite |
| Medtronic Vascular, INC. | $214.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $191.96 | 2019-2023 | Xarelto |
| Pfizer INC. | $189.14 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $186.24 | 2019-2022 | |
| Esperion Therapeutics, INC. | $136.36 | 2021 | |
| Allergan, INC. | $123.50 | 2019 | |
| Biotronik INC. | $117.03 | 2019 | |
| Bard Peripheral Vascular, INC. | $112.65 | 2022 | |
| Amgen INC. | $100.57 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.93 | 2019-2022 | |
| Astellas Pharma US INC | $55.84 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $44.81 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.14 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.17 | 2019 | |
| Cardiva Medical, INC. | $16.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apurva Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.